CONMED Corporation

CNMD Healthcare Medical Devices

CONMED Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 5.18% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 11.6%, free cash flow grew 46.0% and total debt fell 5.40%, each against the same quarter a year earlier. Dividend growth for ten consecutive years, revenue growth for five, operating cash flow growth for three.

46.72 0.42 −0.89%
Market cap
$1.4B
P/E
25.3×
Fwd P/E
8.8×
Dividend yield
0.00%
F-score
5/9
Altman Z
1.86
Beneish M
−2.70
Dividend safety
63/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
5.53% 5.50% 4.72% 6.60%

+8 more TTM periods

Piotroski F-Score
6 6 5 5
ROA
2.44% 2.38% 2.03% 2.76%
ROIC
3.75% 3.80% 3.51% 4.06%
Return on Tangible Assets
17.10% 11.20% 9.99% 13.94%
Average Days of Receivables
63.80 60.90 65.80 60.93
Free Cash Flow per Share
4.47 4.04 4.86 4.81
Free Cash Flow
134.46 123.71 150.88 148.96
Capital Expenditures
(16.12) (18.92) (19.81) (18.73)
Other line items
Cash ROIC
7.03% 6.46% 7.90% 7.84%
Accounts Receivable Turnover
5.79 6.09 5.66 5.91
Accounts Payable Turnover
6.00 6.11 6.37 5.83
Inventory Turnover
1.68 1.70 1.78 1.75
Average Days of Payables
60.81 62.63 54.76 63.36
Days of Inventory on Hand
216.81 217.51 207.89 215.56
Tax Rate
(0.32) (0.33) (0.34) (0.25)
Research and Development Expense of Revenue
4.42% 4.32% 4.07% 4.02%
Selling, General and Administrative Expense of Revenue
43.33% 42.67% 43.06% 41.40%
Share Based Compensation of Revenue
1.48% 1.46% 2.06% 2.19%
Interest Coverage
3.69 3.75 3.30 3.64
Operating CF/Net income
2.67 2.60 3.63 2.62
Depreciation/Fixed assets
0.73 0.72 0.71 0.71
Capex/Depreciation
(0.20) (0.24) (0.25) (0.24)
Revenue per Share
45.62 44.81 44.29 43.53
Operating CF per Share
5.01 4.66 5.50 5.42
Capex per Share
(0.54) (0.62) (0.64) (0.61)
Capex to Sales
0.01 0.01 0.01 0.01

Fold the line items

Columns are period end dates